Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PDE6D | O43924 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11302965 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4079332 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4079319 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL11295264 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4079327 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1021915 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL11302951 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL1021914 | 1.00 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Methylamine SCHEMBL3171823 | 0.99 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| Diethanolamine SCHEMBL3162904 | 0.95 | HMGCR (0.52) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371291-B2 | Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof | ASTRAZENECA UK LIMITED (GB) | 2016-06-21 | — | — | US | claimed |
| EP-2373609-B1 | USE OF AMPHIPHILIC COMPOUNDS FOR CONTROLLED CRYSTALLIZATION OF STATINS AND STATIN INTERMEDIATES | KRKA D D NOVO MESTO (SI) | 2013-10-16 | — | — | EP | claimed |
| EP-1682536-B1 | PROCESS FOR THE MANUFACTURE OF THE CALCIUM SALT OF ROSUVASTATIN (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO] PYRIMIDIN-5-YL](3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATES THEREOF | ASTRAZENECA UK LTD (GB) | 2013-02-27 | — | — | EP | claimed |
| US-20110301348-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | ASTRAZENECA UK LIMITED (GB) | 2011-12-08 | — | — | US | claimed |
| US-8063213-B2 | Reacting (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl) acetic acid with hydrochloric acid, salt formation with sodium or potassium hydroxide, basification, desolventization, salt exchange | ASTRAZENECA UK LIMITED (GB) | 2011-11-22 | — | — | US | claimed |
| EP-2272842-A1 | Process for the manufacture of the calcium salt of rosuvastatin and crystalline intermediates thereof | AstraZeneca UK Limited (GB) | 2011-01-12 | — | — | EP | claimed |
| EP-1902036-B1 | PROCESS FOR THE PREPARATION OF ROSUVASTATIN AND INTERMEDIATES | RICHTER GEDEON NYRT (HU) | 2010-03-24 | — | — | EP | claimed |
| US-20080221323-A1 | Production of Rosuvastatin Calcium Salt | ASTRAZENECA UK LIMITED (GB) | 2008-09-11 | — | — | US | claimed |
| US-6844437-B1 | Process for the production of tert-butyl (E)-(6-[2-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsufonyl)amino]pyrimidin-5-yl]vinyl]4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate | ASTRAZENECA AB (GB) | 2005-01-18 | — | — | US | claimed |
| US-20040049036-A1 | Process for the production of tert-butyl (E)-(6-[2-[4-(-flourophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2, 2-dimethyl[1, 3]oioxan-4yl)acetace | ASTRAZENECA AB | 2004-03-11 | — | — | US | claimed |
| EP-2788342-B1 | PROCESS FOR THE PREPARATION OF A STATIN PRECURSOR | DSM SINOCHEM PHARM NL BV (NL) | 2018-01-24 | — | — | EP | disclosed |
| EP-2788341-B1 | PROCESS FOR THE PREPARATION OF A THIOPRECURSOR FOR STATINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-04-05 | — | — | EP | disclosed |
| EP-2665722-B1 | PROCESS FOR THE PREPARATION OF DIOL SULFONES | DSM SINOCHEM PHARM NL BV (NL) | 2016-08-17 | — | — | EP | disclosed |
| US-9371291-B2 | Process for the manufacture of the calcium salt of rosuvastatin (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-enoic acid and crystalline intermediates thereof | ASTRAZENECA UK LIMITED (GB) | 2016-06-21 | — | — | US | disclosed |
| US-9260423-B2 | Process for the preparation of a thioprecursor for statins | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2016-02-16 | — | — | US | disclosed |
| WO-2005042522-A1 | PROCESS FOR THE MANUFACTURE OF THE CALCIUM SALT OF ROSUVATATIN (E)-7-`4- (4-FLUOROPHENYL) -6-ISOPROPYL-2-`METHYL (METHYLSULFONYL) AMINO ! PYRIMIDIN -5-YL ! (3R, 5S) -3, 5-DIHYDROXYHEPT-6-ENOIC ACID AND CRYSTALLINE INTERMEDIATES THEREOF | ASTRAZENECA UK LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
| US-6844437-B1 | Process for the production of tert-butyl (E)-(6-[2-[4-(4-flurophenyl)-6-isopropyl-2-[methyl(methylsufonyl)amino]pyrimidin-5-yl]vinyl]4R,6S)-2,2-dimethyl[1,3]dioxan-4-yl)acetate | ASTRAZENECA AB (GB) | 2005-01-18 | — | — | US | disclosed |
| US-6784171-B2 | REACTION OF METHYL 2-AMINO-4-(4-FLUOROPHENYL)-6-ISOPROPYL-PYRIMIDINE-5-CARBOXYLATE WITH METHANESULFONYL CHLORIDE IN THE PRESENCE OF STRONG BASE, REACTION OF THE INTERMEDIATE WITH A METHYLATING AGENT IN PRESENCE OF STRONG BASE | ASTRAZENECA (SE) | 2004-08-31 | — | — | US | disclosed |
| US-20040049036-A1 | Process for the production of tert-butyl (E)-(6-[2-[4-(-flourophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2, 2-dimethyl[1, 3]oioxan-4yl)acetace | ASTRAZENECA AB | 2004-03-11 | — | — | US | disclosed |
| EP-1155015-A1 | PROCESS FOR THE PRODUCTION OF TERT-BUTYL (E)-(6-[2-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL]VINYL](4R,6S)-2,2-DIMETHYL[1,3]DIOXAN-4-YL)ACETATE | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221323-A1 | Production of Rosuvastatin Calcium Salt | HMGCR, INPP5D, INPPL1 | HMGCR 1/4885ALDH1A1 2489/4885CYP3A4 2136/4885 |
| US-20110301348-A1 | Process for the Manufacture of the Calcium Salt of Rosuvastatin (E)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-[Methyl(Methylsulfonyl)Amino]-Pyrimidin-5-yl](3R,5S)-3,5-Dihydroxyhept-6-Enoic Acid and Crystalline Intermediates Thereof | HMGCR, DHCR7, GRHPR | HMGCR 1/4885ALDH1A1 1706/4885CYP3A4 1086/4885 |
| US-20040049036-A1 | Process for the production of tert-butyl (E)-(6-[2-[4-(-flourophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)-2, 2-dimethyl[1, 3]oioxan-4yl)acetace | TBXAS1, CYP4B1, DHPS | HMGCR 72/4885ALDH1A1 122/4885CYP3A4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.